D. E. Shaw & Co., Inc. Pacira Bio Sciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 2,263,909 shares of PCRX stock, worth $51 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

2,263,909

Previous 2,257,474 0.29%

Holding current value

$51 Million

Previous $42.5 Million 32.28%

% of portfolio

0.06%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$18.33 - $27.25 $117,953 - $175,353	6,435 Added 0.29%	2,263,909 $56.3 Million
Q4 2024 Feb 14, 2025	BUY	$15.3 - $20.33 $4.6 Million - $6.11 Million	300,536 Added 15.36%	2,257,474 $42.5 Million
Q3 2024 Nov 14, 2024	BUY	$11.7 - $28.46 $17.3 Million - $42 Million	1,476,508 Added 307.33%	1,956,938 $29.5 Million
Q2 2024 Aug 14, 2024	BUY	$25.5 - $31.51 $6.12 Million - $7.56 Million	239,991 Added 99.81%	480,430 $13.7 Million
Q1 2024 May 15, 2024	BUY	$27.7 - $35.48 $953,517 - $1.22 Million	34,423 Added 16.71%	240,439 $7.03 Million
Q4 2023 Feb 14, 2024	BUY	$26.32 - $34.31 $1.29 Million - $1.68 Million	48,954 Added 31.17%	206,016 $6.95 Million
Q3 2023 Nov 14, 2023	BUY	$30.68 - $40.09 $4.66 Million - $6.08 Million	151,753 Added 2858.41%	157,062 $4.82 Million
Q2 2023 Aug 14, 2023	SELL	$36.12 - $47.5 $495,674 - $651,842	-13,723 Reduced 72.1%	5,309 $212,000
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $676,206 - $825,608	19,032 New	19,032 $776,000
Q2 2022 Aug 15, 2022	SELL	$51.49 - $81.64 $599,909 - $951,187	-11,651 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$60.03 - $76.49 $2.28 Million - $2.91 Million	-38,046 Reduced 76.56%	11,651 $889,000
Q4 2021 Feb 14, 2022	SELL	$47.97 - $62.21 $1.44 Million - $1.87 Million	-30,036 Reduced 37.67%	49,697 $2.99 Million
Q3 2021 Nov 15, 2021	SELL	$54.64 - $61.3 $4.52 Million - $5.08 Million	-82,790 Reduced 50.94%	79,733 $4.47 Million
Q2 2021 Aug 16, 2021	SELL	$59.18 - $69.99 $25.8 Million - $30.5 Million	-436,006 Reduced 72.85%	162,523 $9.86 Million
Q1 2021 May 17, 2021	SELL	$59.31 - $78.82 $15.4 Million - $20.4 Million	-259,427 Reduced 30.24%	598,529 $42 Million
Q4 2020 Feb 16, 2021	SELL	$50.47 - $66.26 $725,556 - $952,553	-14,376 Reduced 1.65%	857,956 $51.3 Million
Q3 2020 Nov 16, 2020	SELL	$51.97 - $63.0 $5.1 Million - $6.18 Million	-98,053 Reduced 10.1%	872,332 $52.4 Million
Q2 2020 Aug 14, 2020	SELL	$30.8 - $52.47 $2.36 Million - $4.02 Million	-76,598 Reduced 7.32%	970,385 $50.9 Million
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $2.3 Million - $4.11 Million	-81,025 Reduced 7.18%	1,046,983 $35.1 Million
Q4 2019 Feb 14, 2020	SELL	$36.31 - $46.83 $3.62 Million - $4.67 Million	-99,732 Reduced 8.12%	1,128,008 $51.1 Million
Q3 2019 Nov 14, 2019	SELL	$35.66 - $44.99 $742,904 - $937,276	-20,833 Reduced 1.67%	1,227,740 $46.7 Million
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $11.2 Million - $14.7 Million	306,129 Added 32.48%	1,248,573 $54.3 Million
Q1 2019 May 15, 2019	BUY	$36.47 - $42.17 $20.8 Million - $24 Million	570,237 Added 153.2%	942,444 $35.9 Million
Q4 2018 Feb 14, 2019	BUY	$41.31 - $52.16 $8.64 Million - $10.9 Million	209,170 Added 128.3%	372,207 $16 Million
Q3 2018 Nov 14, 2018	BUY	$32.85 - $52.0 $5.36 Million - $8.48 Million	163,037 New	163,037 $8.01 Million
Q2 2018 Aug 14, 2018	SELL	$27.5 - $39.8 $539,440 - $780,716	-19,616 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$29.98 - $46.35 $68,474 - $105,863	-2,284 Reduced 10.43%	19,616 $611,000
Q4 2017 Feb 14, 2018	BUY	$31.85 - $46.95 $383,760 - $565,700	12,049 Added 122.31%	21,900 $1 Million
Q3 2017 Nov 14, 2017	BUY	$35.7 - $39.5 $351,680 - $389,114	9,851	9,851 $370,000

Others Institutions Holding PCRX

# of Institutions

256

Shares Held

51M

Call Options Held

157K

Put Options Held

139K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.03B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account